logo

Breaking News

Share SHARE

Unibail-Rodamco SE (UNBLF.PK) reported that its first-half net result to owners of the parent increased to 1.46 billion euros from 1.28 billion euros, prior year. Net result for the period per share was 14.0 euros compared to 12.4 euros. Recurring net result increased to 614 million euros from 575 million...

Merck (MRK) reported that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its pre-specified primary endpoint of overall survival....

HNI Corp. (HNI) announced the Corporation estimates full year non-GAAP earnings per share to be in the range of $2.35 to $2.55, which excludes restructuring and transition costs. Full year organic sales are expected to be up 2 to 5 percent. Including the impacts of acquisitions and divestitures, full...

Novavax, Inc. (NVAX) announced positive topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, new preclinical data on its RSV F Vaccine construct, additional findings from the prior Phase 2 and Phase 3 clinical trials in older adults, and an operational update...

Hexcel Corp. (HXL) announced the company's Board has approved a 13.6 percent increase in quarterly cash dividend rate to $0.125 per common share. The dividend is payable on August 10, 2017 to stockholders of record as of August 3, 2017. Hexcel Corp. also revised its full year sales outlook to be...

QEP Resources, Inc. (QEP) announced its subsidiary, QEP Energy Company, has entered into two definitive agreements to sell natural gas assets in southwest Wyoming for combined proceeds of $777.5 million. The first agreement provides for the sale of all of QEP's assets in the Pinedale Anticline field...

Hibbett Sports Inc. (HIBB) said that it expects comparable store sales to decrease approximately 10% for the second quarter ending July 29, 2017, citing very challenging sales trends. In the pre-Market trade, HIBB is trading at $15.10, down $4.60 or 23.35 percent. The decline in sales, along with...

Pfizer Inc. (PFE) said that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin. The trial demonstrated equivalence...

Merck & Co. Inc. (MRK) announced Monday the U.S. launch of RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab). RENFLEXIS was approved by the U.S. Food and Drug Administration on April 21 for all eligible indications. RENFLEXIS is the first medicine...

ParkerVision, Inc. (PRKR), a manufacturer of semiconductor technology solutions for wireless applications, provided an update to its on-going patent licensing program by saying it has re-filed its claims against LG Electronics (LGEPF.OB, LGEJY.OB, LGEIY.OB, LGEAF.OB) and related entities in the District...

Lennox International Inc. (LII) announced the company raised the low end of its 2017 adjusted EPS from continuing operations guidance to $7.75-$8.15 from $7.55-$8.15. The company narrowed guidance for GAAP EPS from continuing operations to $7.73-$8.13 from $7.65-$8.25. For 2017, Lennox raised 2017 guidance...

Cytori Therapeutics Inc. (CYTX) announced preliminary data from its pivotal STAR trial of HabeoTM Cell Therapy in patients with scleroderma. While the primary endpoint, Cochin Hand Function Score (CHFS), did not reach statistical significance at 24 or 48 weeks, the trial data reported clinically meaningful...

Eli Lilly and Co. (LLY) and Nektar Therapeutics (NKTR) Monday announced a strategic collaboration to co-develop NKTR-358, an immunological therapy discovered by Nektar. The compound is intended to reat a number of autoimmune and other chronic inflammatory conditions. Under the terms of the agreement,...

VF Corp. (VFC) announced that Eric Wiseman will retire as Executive Chairman of the Board and as a Director, effective October 28, 2017. VF's Board has elected President, Chief Executive Officer and Director Steven Rendle, to the role of Chairman effective upon Wiseman's retirement. Wiseman began...

Genocea Biosciences Inc. (GNCA) announced positive 12-month top-line data from the Phase 2b clinical trial for GEN-003, its immunotherapy candidate for patients with genital herpes. In this 131-subject Phase 2b clinical trial, GEN-003 reduced the median genital lesion rate (or percent days with genital...

Follow RTT